NOVO — Februar 2026
-
Pokkers, det kan jeg ikke se. Jeg sidder fra iPhone og iPad. Jeg kan fx nu kun se tilbage til kl. 15:40 i går.
-
Du burde kunne se det. Det var i går: 19/2 2026 21:24 af ProinvestorNEWS
Novo Nordisk, Eli Lilly Sending Cease-and-Desist Letters Over Compounded Semaglutide (link) -
Super. Skal jeg have fikset. Misser meget info på den front.
-
Bruger det rullenedvindue/mindre vindue i højre side,
hvor Novo er nr 51 at vælge mellem -
Du kan gå til chathistorik. Her kan du på fuld skærm læse tilbage til 2009.
-
-
Recepttal for Wegovy-pillen vidner om stærk vækst men fortæller ikke alt pointerer analytiker https://proinvestor.com/investornyt/1413708/recepttal-for-wegovy-pillen-vidner-om-staerk-vaekst-men-fortaeller-ikke-alt-pointerer-analytiker
-
Novo nærmer sig vigtige data: Danske Bank spår tæt løb https://proinvestor.com/investornyt/1413710/novo-naermer-sig-vigtige-data-danske-bank-spar-taet-lob
-
$NVO gets a price target cut from David Evans at Kepler Cheuvreux.
PT lowered to DKK 400 from DKK 430, with the Buy recommendation maintained.
-
Winkel foreslået til Novos bestyrelse https://borsen.dk/nyheder/virksomheder/novo-foreslar-genmab-topchef-til-bestyrelsen
-
Novo Nordisk vil have Genmabs topchef i bestyrelsen https://proinvestor.com/investornyt/1413719/novo-nordisk-vil-have-genmabs-topchef-i-bestyrelsen
-
Kontra
@KontraInvest
$NVO: The Oral revolution is realThe latest IQVIA data (week ending Feb 13, 2026) confirms what we've been waiting for: The Wegovy pill is indeed a massive market expander.
Total Wegovy TRx hit 319,621 (+11.9% week over week), driven largely by the pill's HUGE growth in its sixth week. -
Key Insights:
Pill power: Wegovy pill TRx reached 56,943, a +49% jump week-over-week. This accounted for nearly 18% of total Wegovy prescriptions.Market share shift: Wegovy’s share of weekly TRx rose to 36.6% (up from 33.2%), while Zepbound saw a -3.8% decrease to 552,809.
-
Expansion, not cannibalization: Injectable volume is still growing alongside the pill. The oral form factor is bringing in sidelined patients who were needle-avoidant, not just switching existing users.
Starter dose dominance: Novo gained 16k in starter dose TRx while Lilly lost 4k. This is the lead indicator for future long-term volume.
These are very strong numbers and indicators!.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind